Rossol S
Medizinische Klinik, Krankenhaus Nordwest, Frankfurt am Main, Germany.
Gesundheitswesen. 2007 Mar;69(3):146-50. doi: 10.1055/s-2007-971069.
In Germany up to 800,000 persons are chronically infected with the hepatis C virus. This chronic disease is correlated with a significant morbidity and mortality. This is a consequence of the development of liver cirrhosis and hepatocellular carcinoma in a substantial proportion of the patients. Health quality of life is also affected by the infection. There are reliable standards available for diagnosis and treatment. Antiviral treatment is highly effective and the combination of pegylated interferon alpha with ribavirin leads to a sustained viral eradication in about 60% of the cases. The treatment is also cost-effective and results in an increased life expectancy. Costs for HCV treatment are favourable in comparison to other well accepted therapies and interventions and a reduction of future costs can be expected.Thus, active screening for HCV infected persons should be intensified to improve the quality of medical care. Early and broad treatment is potentially able to reduce the future burden of HCV-related diseases.
在德国，多达80万人长期感染丙型肝炎病毒。这种慢性疾病与显著的发病率和死亡率相关。这是相当一部分患者发展为肝硬化和肝细胞癌的结果。感染还会影响生活质量。目前有可靠的诊断和治疗标准。抗病毒治疗非常有效，聚乙二醇化干扰素α与利巴韦林联合使用可使约60%的病例实现持续病毒清除。该治疗还具有成本效益，并能延长预期寿命。与其他广泛接受的治疗和干预措施相比，丙型肝炎治疗的成本较低，预计未来成本会降低。因此，应加强对丙型肝炎感染者的主动筛查，以提高医疗质量。早期和广泛的治疗有可能减轻未来丙型肝炎相关疾病的负担。
